Leukemia in the Omics Era: From Mechanisms to Therapies
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 2
Special Issue Editor
2. Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy
Interests: molecular treatments of acute leukemias; measurable residual disease in leukemia; molecularly targeted agents in chronic lymphocytic leukemia; molecularly targeted agents in myeloproferative disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Recent advances in basic research on acute and chronic leukemias have enabled the development of molecularly targeted therapies that now represent the cornerstone of treatment in selected clinical settings. The goal of this Special Issue is to provide a state-of-art overview of key preclinical research on targeted agents in leukemia, together with current clinical developments in the field.
Topics of interest include, but are not limited to, the following:
- Mechanism exploration (with a focus on the molecular mechanisms underlying leukemia occurrence, progression, and heterogeneity)
- Omics-based dissection of leukemia pathogenesis;
- Leukemia stem cell biology and molecular regulatory mechanisms;
- Epigenetic modifications in leukemia development;
- Drug resistance mechanisms;
- Single-cell analysis of leukemia heterogeneity and clonal evolution;
- Non-coding RNAs in the regulation of leukemia progression;
- Measurable residual disease (mechanisms of persistence and recurrence).
- Therapeutic strategies (with a focus on the development, optimization, and translation of leukemia treatments)
- Molecular treatments of acute leukemias;
- Molecularly targeted agents in chronic lymphocytic leukemia;
- Molecularly targeted agents in myeloproliferative disease;
- Immunotherapeutic strategies for leukemia: molecular mechanisms and clinical translation;
- Molecularly guided reversal strategies for leukemia drug resistance;
- Molecular biomarkers for leukemia treatment response prediction.
- Technology application (with a focus on technical tools driving leukemia research and clinical practice)
- Omics technologies for leukemia research;
- Single-cell technologies in leukemia heterogeneity analysis;
- Molecular detection technologies for measurable residual disease in leukemia;
- Molecular diagnostic technologies for leukemia (based on biomarkers);
- Molecular technologies for predicting leukemia prognosis.
Dr. Marco Rossi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- FLT3 inhibitors
- JAK inhibitors
- BTK inhibitors
- BCL 2 inhibitors
- BTK degraders
- menin inhibitors
- IDH inibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
